Cognitive function is markedly impaired in most patients with schizophrenia. Antecedents of this impairment are evident in childhood. The cognitive disability is nearly fully developed at the first episode of psychosis in most patients. The contribution of cognitive Impairment to outcome in schizophrenia, especially work function, has been established. Preliminary results indicate that cognitive function, along with disorganization symptoms, discriminate schizophrenia patients who are able to work full-time from those who are not. Typical neuroleptic drugs lack the ability to improve the various domains of cognitive function impaired in schizophrenia. Atypical antipsychotic drugs pharmacologically related to clozapine-quetlapine, olanzapine, risperidone, sertindole, and ziprasidone-share the ability to produce fewer extrapyramidal symptoms than typical neuroleptic drugs and more potent antagonism of serotonin^ relative to dopamine 2 receptors. However, they have a number of different clinical effects. We have identified all the studies of clozapine, olanzapine, and risperidone that provide data on their effects on cognition in schizophrenia. Data for each drug are reviewed separately in order to identify differences among them in their effects on cognition. Twelve studies that report cognitive effects of clozapine are reviewed. These studies provide (1) strong evidence that clozapine Improves attention and-verbal-fluency and (2) moderate evidence that clozapine improves some types of executive function. However, results of the effects of clozapine on working memory and secondary verbal and spatial memory were inconclusive. Risperidone has relatively consistent positive effects on working memory, executive functioning, and attention, whereas improvement in verbal learning and memory was inconsistent Preliminary evidence presented here suggests that olanzapine improves verbal learning and memory, verbal fluency, and executive function, but not attention, working memory, or visual learning and memory. Thus, atypical antipsychotic drugs as a group appear to be superior to typical neuroleptics with regard to cognitive function. However, available data suggest that these drugs produce significant differences in specific cognitive functions. These differences may be valuable adjunctive guides for their use in clinical practice if cognitive improvements reach clinical significance. The effects of the atypical antipsychotic drugs on cholinergic and 5-HT 2a -mediated neurotransmission as the possible basis for their ability to improve cognition are discussed. It is suggested that the development of drugs for schizophrenia should focus on improving the key cognitive deficits in schizophrenia: executive function, verbal fluency, working memory, verbal and visual learning and memory, and attention.
the premorbid ability of schizophrenia patients to work or attend school successfully or to have satisfactory interpersonal function. Thus, although typical neuroleptic drugs are effective in treating positive symptoms in about 70 percent of schizophrenia patients (Meltzer 1997) , no more than 30 percent of schizophrenia patients are able to hold part-or full-time jobs (Mulkern and Manderscheid 1989; Rupp and Keith 1993) . For example, only 51.8 percent of first-episode schizophrenia patients were reported to recover functionally 1 year after the onset of psychosis (Tohen et al. 1997) . Recent-onset patients with schizophrenia (i.e., those with a duration of illness of less than 5 years) are only slightly more able to hold volunteer or paying jobs than chronic, neuroleptic-resistant schizophrenia patients (Meltzer et al., in preparation) .
Cognitive Impairment and Functional Deficits in Schizophrenia
Patients with schizophrenia have widespread, multifaceted impairments in many domains of neurocognitive function, including executive function, attention, perceptual/motor processing, vigilance, verbal learning and memory, verbal and spatial working memory, and semantic memory (verbal fluency) (Braff et al. 1991; Kenny and Meltzer 1991; Saykin et al. 1994) . There is increasing awareness of the critical importance of cognitive dysfunction in schizophrenia. Evidence suggests that various forms of cognitive impairment, such as verbal learning and memory, executive function, and vigilance, may be of equal or greater importance than positive or negative symptoms in predicting functional outcomes, such as work status, activities of daily living, community outcome, and social problem solving and skill acquisition (Lysaker et al. 1995; Green et al. 1996; Velligan et al. 1997) .
Cognition and Work Function in Schizophrenia.
The relationship between work function and cognitive function at baseline in a group of 82 neuroleptic-resistant schizophrenia patients (most of whom were medication free, with a few receiving typical neuroleptic drugs) following 12 months of treatment with clozapine has previously been reported . Of this group, 15 patients (18.3%) were employed full time, 13 (15.9%) were employed part time, and 54 (65.9%) were unemployed at 12 months. The baseline (i.e., pre-clozapine) Wisconsin Card Sort Test (WCST; Heaton 1981) Categories score, a measure of executive function, was significantly better in those employed full time compared with those employed part time and the unemployed. There were no differences in eight other cognitive measures.
The following test scores were significantly better in those employed full-time at 12 months compared with the unemployed group: the Wechsler Intelligence Scale for Children-Revised (WISC-R; Wechsler 1974 (Bushke and Fuld 1974) . Those patients employed part time or in school did not differ from either group. The relationship between cognitive test performance and work status remained the same when 12-month cognitive test scores were evaluated (Meltzer et al., in preparation) .
We further examined the relationship between cognition, symptoms, and work status in a group of 243 schizophrenia patients: Of these, 39 were employed or volunteering at least 20 hours per week, and 206 had been unemployed for at least 1 year. The groups did not differ in age, gender, or age at illness onset. Those who were working had a shorter duration of illness (9.2 ± 6.2 (mean ± standard deviation [SD] ) vs. 12.9 ± 8.1 years, p < 0.01). The employed group had fewer hospitalizations (3.9 ± 5.2 vs. 7.7 ± 8.4, p < 0.01), lower Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) positive symptom scores (9.4 ± 5.6 vs. 11.0 ± 5.4, p < 0.05), and lower disorganization scores on the Schedule for Affective Disorders and SchizophreniaChange (SAD-C; Endicott and Spitzer 1978) (2.1 ± 2.9 vs. 3.1 ± 3.5, p < 0.05). Those who were employed had better performance on the WCST-Categories (2.8 ± 2.3 vs. 3.7 ± 2.5, p < 0.05) and VLL-DR (6.4 ± 3.3 vs. 7.5 ± 3.2, p = 0.04) and tended to have better performance on the VLL-IR (7.5 ± 2.5 vs. 8.3 ± 2.3, p < 0.06). After adjusting for duration of illness and BPRS positive symptom scores, WCST-Categories, VLL-IR, and VLL-DR scores were still higher for those patients who were employed (data not presented). Thus, executive functioning and verbal learning and memory, as reported by Green (19%) , appeared to be a useful predictor of work status, independent of positive symptoms.
pled to adenylate cyclase) will be referred to as typical antipsychotics or as neuroleptics, to distinguish them from atypical antipsychotic drugs. Atypical antipsychotics are operationally denned as drugs that produce minimal extra pyramidal symptoms (EPS) at doses that produce effective antipsychotic action (Meltzer 1995a) . The prototypical atypical antipsychotic drug is clozapine (Meltzer 1997) . Other members of the class include olanzapine, quetiapine, risperidone, sertindole, and ziprasidone. These drugs share potent S-HT^ and relatively weaker D 2 receptor antagonism (Meltzer et al. 1989; Schotte et al. 1996) . Other compounds with a similar profile that have had lesser clinical testing include melperone, amperozide, iloperidone, and the selective 5-HT 2a antagonist M 100907 (Meltzer and Fatemi 1996) . All such compounds cause low EPS at doses that have an antipsychotic action equivalent or superior to haloperidol or similar drugs. Thioridazine, which has the least EPS of any commonly used first-generation antipsychotic drug, is not considered atypical because its potential to produce EPS is significantly greater than that of the atypical antipsychotic drugs listed above (Scholz and Dichgans 1985) .
Studies comparing cognitive function in neurolepticfree schizophrenia patients with patients treated with typical antipsychotics have been reviewed by Heaton and Crowley (1981) , Spohn and Strauss (1989) , Cassens et al. (1990) , King (1990) , Bilder et al. (1992) , and Mortimer (1997) . The clear consensus of this body of research is that neither acute nor chronic administration of typical antipsychotics produced much beneficial effect on cognition. Moreover, there is some evidence that they cause selective impairment of some cognitive functions, particularly motor function and memory (Heaton and Crowley 1981; Earle-Boyer et al. 1991) . Those antipsychotic drugs, such as thioridazine, with an appreciable anticholinergic effect have more adverse effects on memory (Spohn and Strauss 1989; Eitan et al. 1992) . Lee et al. (1994, in press) found no worsening with typical neuroleptic drugs on any measure studied. Transient improvement in VLL-IR was noted during a 12-month treatment period in 29 recent-onset schizophrenia patients, who responded extremely well to these drugs. Their minimal change in cognition, despite near-complete control of positive symptoms in the group as a whole, provides further evidence that cognition is largely independent of positive symptoms.
Atypical Antipsychotic Drugs
Pharmacological differences in relation to clinical effects. All atypical antipsychotic drugs produce an antipsychotic effect at doses that do not cause significant EPS in the majority of patients with schizophrenia. However, there are differences in these drugs' ability to spare the motor system. Thus, clozapine appears least likely to produce EPS or even tardive dyskinesia (Lieberman et al. 1991) , whereas risperidone may produce EPS in the higher range of doses used, for example, a 8 mg/day (Marder and Meibach 1994) . Olanzapine, quetiapine, low-dose risperidone, and ziprasidone appear to be more similar to clozapine with regard to EPS potential. However, at this time, it is not clear to what extent they may produce tardive dyskinesia (Beasley et al. 1996; Arvanitis and Miller 1997; Davis and Markham 1997; Tandon et al. 1997) . There is some evidence that olanzapine may have a lower risk of causing tardive dyskinesia than does haloperidol (Tollefson et al. 1997a) .
Differences in the potential to produce EPS reflect differences in pharmacology of these agents (Meltzer et al. 1989; Roth et al. 1992 Roth et al. , 1994 Roth et al. , 1995 Schotte et al. 1996) , which have been reviewed elsewhere (Meltzer and Fatemi 1996; Schotte et al. 1996) . Considering only in vitro based affinities, clozapine has the broadest spectrum of action of any of these agents, including high affinities (< 50 nM) for S-HT^, S-HT^, 5-HT 6 , 5-HT 7 , M,-M 5 , alphaj-adrenergic, histamine Hj, and D 4 receptors. Olanzapine has high affinity for 5-HT 2a , 5-HT 6 , D 2 , M,-M 5 , and Hj receptors. Risperidone has high affinity for the 5-HT^, 5-HT 7 , D 2 , D 3 , alpha,-and alpha 2 -adrenergic, and H, receptors. Ziprasidone has high affinities for the 5-HT la , 5-HT^, 5-HT^, 5-HT ld , 5-HT 7 , D 2 , and D 3 receptors and moderate affinities for alphaj-adrenergic and H[ receptors and for the 5-HT and norepinephrine (NE) reuptake transporters (Roth et al. 1995; Seeger et al. 1995) . Quetiapine is a low-potency agent with high affinity only for the Hj receptor (19 nM). Its affinities for the alpha, adrenergic, and S-HT^ receptors are slightly less-58 and 120 nM, respectively (Schotte et al. 1996) . These effects are summarized in table 1. It is apparent that the only receptors for which all the agents have a high in vitro affinity are the H, receptor and, with the exception of quetiapine, the 5-HT^ receptor.
As we have discussed elsewhere (Stockmeier et al. 1993) , knowledge of the in vitro profiles of the atypical antipsychotic drugs may be insufficient to predict their in vivo effects. At high enough doses, they are capable of affecting other receptors as well. There may also be many regional differences in vivo thatmay reflect differences in the ability of these agents to modulate the release and reuptake of neurotransmitters at whose receptors they are usually antagonists, but sometimes agonists, through direct or indirect agonist actions. As indicated above, ziprasidone and clozapine have multiple effects on the serotonergic system, including antagonism at 5-HT 2a , 5-HT 2c , and 5-HT 7 (and in the case of ziprasidone, 5-HT ld ) but also direct or indirect 5-HT agonist effects at 5-HT la receptors. We discuss below how clozapine, which is often thought of as a potent antimuscarinic agent (Miller and Hiley 1974) , may, in vivo, act more as an indirect cholinomimetic agent. Simplistic pharmacological predictions based on considerations of the effects of specific agents on target receptors (e.g., selective S-HTâ ntagonists such as M 100907) are belied by the complex interactions of 5-HT, DA, NE, glutamate, gammaaminobutyric acid (GABA), and acetylcholine (ACh), which vary in different brain regions.
The differences in pharmacology are likely to be the basis for important clinical differences among the newer atypical antipsychotic drugs. For example, clozapine is the only atypical antipsychotic drug that so far has been more effective than typical neuroleptic drugs in treatmentresistant patients in a double-blind trial with an active comparator. Clozapine was better able to decrease positive and negative symptoms in treatment-resistant schizophrenia patients (Kane et al. 1988 ). This is not to say that other atypical antipsychotic drugs are not effective in some of these patients as well, but clinical experience suggests their efficacy in this patient group is less frequent than that of clozapine. In addition, withdrawal of clozapine is more likely to produce an exacerbation of psychosis than is withdrawal of typical neuroleptics, risperidone, olanzapine, or quetiapine . Clozapine is much better tolerated in patients with Parkinson's disease who have an L-dopa-induced psychosis than is either risperidone or olanzapine (Pfeiffer and Wagner 1994 ; J.H. Friedman personal communication, 4/1/98). Clozapine is the least likely of these drugs to produce tardive dyskinesia (Lieberman et al. 1991) . Clozapine, quetiapine, olanzapine, and ziprasidone do not significantly increase serum prolactin levels in patients when given chronically (Meltzer et al. 1979; Arvanitis and Miller 1997; Davis and Markham 1997; Tran et al. 1997) , but risperidone does (Peuskens 1995) . Olanzapine and clozapine are most likely to produce large weight gain; risperidone is less so (Peuskens 1995; Meltzer 1997) , and ziprasidone has little effect on weight (Davis and Markham 1997; Tandon et al. 1997) .
These important pharmacological differences may be relevant to effects on cognition. Various cognitive measures have been shown to be sensitive to the action of 5-HT (Buhot 1997) , DA (Sawaguchi and Goldman-Rakic 1991; Murphy et al. 1997) , ACh (Sarter and Bruno 1997) , and glutamate (Abi-Dargham et al. 1997) . The pharmacological profiles of the current generation of atypical antipsychotic drugs have some similarities (e.g., relatively potent S-HT^ compared with D 2 affinity) but, as noted above, important differences as well (e.g., antimuscarinic properties). The complex pharmacology of cognition, many components of which require motor function that may be impaired by EPS, suggests that these agents could have important differences in their effects on cognition.
The rest of this article will evaluate published studies on clozapine and risperidone, and present preliminary reports of data from this laboratory on olanzapine and risperidone, to determine whether the prediction of unique effects on cognition is, in fact, confirmed. Elsewhere in this issue, the consideration of the differential effect of the atypical antipsychotic drugs complements and extends the approach of Keefe etal. (1999, this issue) , who considered these drugs as a class, as were the typical neuroleptic drugs in the reviews cited above. Keefe et al. (1999, this issue) combined cognitive performance study data across drugs in a meta-analysis. It is our hypothesis that differences between atypical antipsychotic drugs with regard to cognition are of central importance for both theoretical and clinical reasons.
Clozapine.
We identified 12 studies, published or in press, in which the effects of clozapine on various cognitive measures have been evaluated (table 2). The study of Lee et al. (1994) was a preliminary report based on a partial sample of recent-onset patients with schizophrenia. Data on the full sample is now available (Lee et al., in press) and will be commented on where differences have emerged. Of the 12 studies, 5 included a comparison group treated with another antipsychotic drug (Buchanan et al. 1994; Lee et al. 1994; Daniel et al. 1996; MeyerLindenberg et al. 1997; Lindenmayer et al. 1998 ), 1 was a single-blind crossover study (Daniel et al. 1996) , and 7 were open trials with no comparator. The Zahn et al. (1994) study was a crossover study involving fluphenazine and clozapine. The sample sizes ranged from 10 to 36. The total number of subjects treated with clozapine was 263. Two studies included neurolepticresponsive patients (Lee et al. 1994; Galletly et al. 1997) , whereas the others evaluated only neuroleptic-resistant patients. The baseline cognitive assessment was conducted on neuroleptic-treated patients in all but two of the studies (Hagger et al. 1993; Lee et al. 1994) . Only one study was conducted in a double-blind fashion (Buchanan et al. 1994) and that was only for the first phase of the study, which was 10 weeks in duration. In seven studies, treatment lasted from 6 to 12 weeks. Five studies examined the effects of clozapine at longer intervals, ranging from 6 to 14 months. One study (Goldberg et al. 1993) included subjects treated with multiple drugs in addition to clozapine. Specific neuropsychological assessments were grouped according to the following cognitive domains: (1) attention, (2) executive function, (3) working memory, (4) verbal learning and memory, (5) visual learning and memory, (6) semantic memory, (7) perceptual/motor processing, and (8) reaction time. The specific tests and a summary of results are listed in table 3. Several studies selected identical measures to assess the domains of perceptual7motor processing (e.g., DSST) and executive function (e.g., WCST).
Before summarizing the results, several methodological issues require comment. First, it is our opinion that drug comparison studies require a double-blind, randomized design. We are not aware of any evidence that suggests that cognitive test results in schizophrenia patients will be biased if the investigator knows what medication the patient is receiving. However, such knowledge could differentially affect how comparative studies are conducted and which patients persist in a trial. It is often very difficult to persuade early terminators to repeat the cognitive assessments. Therefore, cognitive studies are overrepresented with subjects who complete the study, most of whom would more likely be responders in terms of psychopathology or other key outcome measures. Investigators should report the number of dropouts in studies comparing two or more antipsychotic agents, especially studies sponsored by industry. A disparity in dropout rates between groups in a nonblinded study might reflect bias due to selective termination of one group of patients.
The second methodological issue is the duration of the trials. Those studies that examined the effects of atypical antipsychotic drugs usually found significant shortterm benefits (e.g., 4-10 weeks), with a different pattern and a slightly greater extent of response after 6 to 12 months. Short-term studies nevertheless appear to be highly informative as to what domains of cognition, if any, are affected by the agents. A shorter study lends itself well to randomized, double-blind efficacy studies. However, longer studies are clearly the most relevant in determining the clinical significance, if any, of cognitive changes that emerge during treatment.
Finally, concomitant medications are likely to seriously confound these studies. Drugs likely to be combined with atypical antipsychotics (e.g., other antipsychotics, antidepressants, mood stabilizers, benzodiazepines, anticholinergics, and beta-blockers, many of which are 5-HT )a antagonists) may have independent effects on cognition. These drugs are also likely to influence critical effects of atypical antipsychotics on neurotransmitters, such as DA, 5-HT, and ACh, which are the most likely basis for the effects these drugs have on cognition. The negative results of Goldberg et al. (1993) , with regard to the effects of clozapine on cognition, may be an example of this.
Perceptual/motor processing, attention, and reaction time. As shown in table 3, 6 of 10 studies (60%) found significant improvement in perceptual/motor processing, as measured by the DSST; in attention, as measured by the Digit Span subtest of the Wechsler Adult Intelligence Scale-Revised (WAIS-R; Wechsler 1981); or in reaction time. It should be noted that the Digit Span is considered by some to be a measure of working memory. Goldberg et al. 1993 Haggeret at. 1993 Lee et al. 1994 Grace et al. 1996 Hoffetal. 1996
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Galletly et al. 1997
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Daniel etal. 1996 Grace et al. 1996 Fujiietal. 1997 Galletly et al. 1997 Lindenmayer et al. 1998 Verbal fluency Goldberg et al. 1993 Haggeretal. 1993 One study, which included a continuous performance test (CPT), found no improvement (Daniel et al. 1996) . The average effect size was about 0.5 SD, and the mean improvement was 15 to 20 percent over baseline. No study found worsening; however, because these effects are mean group differences, it is likely that some patients did worsen. The final scores were still significantly lower than normal control levels when the latter data were provided. The three studies that did not find an effect on any of these measures- Goldberg et al. (1993) , Daniel et al. (1996) , and Lindenmayer et al. (1998) -also found no improvement with clozapine on any other type of cognitive measure. Executive function. Of the 12 studies listed in table 2, 11 examined at least one measure of executive functioning. Five studies (45.4%) found improvement, two studies found a trend (Buchanan et al. 1994; Fujii et al. 1997) , and four found no improvement or worsening. Only one study (Lee et al. 1994) found significant improvement in the WCST-Percent Perseveration. However, this was not confirmed in the full sample (Lee et al., in press; Lindenmeyer et al. 1998) . One study (Fujii et al. 1997) found a trend for improvement in the WCST on both Categories and Perseverative Errors.
Altogether, five studies examining the effect of clozapine on the WCST-Categories or Percent Perseveration found no improvement Fujii et al. (1997) also found a significant improvement in the Similarities subtest of the WAIS-R. Mixed results were found with the Trails B test (The Adjutant General's Office 1944). Two of three studies that examined the ability to perform maze tasks showed improvement with clozapine treatment. Gallhofer et al. (1996) provided cross-sectional data consistent with a beneficial effect of clozapine on maze performance. No improvement, and even some worsening, on the Stroop Color-Word Interference test was found. We can conclude that clozapine may improve some types of executive functioning, but not WCST-Categories (see below).
Working memory. Four studies examined the effect of clozapine on verbal working memory, using the Auditory Consonant Trigrams Test (ACTT; Peterson and Peterson 1959) (table 3) . Two reported improvement, and two did not. Hagger et al. (1993) and Lee et al. (1994) found slight worsening of verbal working memory after 6 weeks of treatment. However, scores reverted to baseline levels after 6 months of treatment. Lee et al. (in press) found no effect on working memory at either 6 weeks or 6 months in a larger sample of neuroleptic-responsive, clozapine-treated patients than was included in the earlier report. Galletly et al. (1997) , however, reported significant improvement in the ACTT after a mean of 6.5 months of treatment. Grace et al. (1996) also reported improvement in verbal working memory using the WAIS-R Digit Span Backward subtest after 2 years of treatment. It may be that a beneficial effect of clozapine on working memory is apparent only after a prolonged period of treatment. It seems unlikely that neuroleptic resistance is a major factor in this domain of cognition because the patients of Lee et al. (1994) responded well to typical neuroleptics prior to clozapine.
Verbal and visual learning and memory. Four of seven studies (57.1%) reported significant improvement on measures of verbal learning and memory (table 3) , including immediate and delayed recall. The improvement due to clozapine was approximately 0.5 SD, but it did not normalize scores. The studies that found clozapine ineffective used relatively more complex assessments of verbal learning and memory, such as paired associates and paragraph memory tests.
Eight studies examined the effect of clozapine on visual learning and memory (table 3) . The results ranged from significant worsening in two studies (25%) to significant improvement in three studies (37.5%). Three studies (37.5%) reported no effect. Two of the studies with positive effects had longer duration of treatment (Buchanan et al. 1994; Grace et al. 1996) . The one positive study with a relatively short duration (Galletly et al. 1997) included nontreatment-resistant patients. We can conclude that clozapine may improve verbal memory tasks of lesser difficulty and possibly after a longer duration of treatment.
Verbal fluency. Six of seven studies (85.7%) that examined the effect of clozapine on verbal fluency reported significant improvement (table 3). All six positive studies utilized the CWAT, which involves letter fluency (generating words beginning with the letters F, A, or S). Improvement was noted in four of five studies for the CIGT, a test of category fluency. Improvements in both tests were approximately 0.5 SD and brought the performance levels to less than 0.5 SD below the mean for the normal controls included in the study. For example, in the Hagger et al. (1993) study, which was the first to report this effect of clozapine, scores on the CWAT increased from 30.4 ± 14.1 to 37.6 ± 14.2 at 6 months, a 23 percent improvement. Normal control scores were 43.9 ± 12.2. This is the most robust and consistent effect on cognition reported with clozapine or any other antipsychotic drug reported thus far.
Motor functioning. Two studies evaluated the effects of clozapine on a measure of motor functioning, the Finger Tapping Test. Hoff et al. (1996) found significant improvements on this task following clozapine treatment, whereas Fujii et al. (1997) did not.
Summary. Clozapine was found to have a robust effect on two cognitive domains, verbal fluency and attention. There was also evidence for its ability to improve some types of executive function and verbal learning and memory. There was little evidence of improvement in working memory. No study found improvement in every cognitive domain. On the other hand, three studies failed to find a significant effect of clozapine on any cognitive measure. These studies differed in some ways from the studies with positive findings. Of the 15 patients in the Goldberg et al. (1993) study, 12 received one of the following psychotropic agents: lithium, fluoxetine, lorazepam, valproate, primidone, or levothyroxine. Patients in the Daniel et al. (1996) study received valproic acid, fluoxetine, paroxetine, sertraline, clonazepam, or clorazepate. The interaction these drugs may have had with clozapine could have influenced cognitive performance. However, the Fujii et al. (1997) study, in which clozapine was found to improve executive function and attention, included two patients who were receiving valproic acid and one receiving clonazepam. The Daniel et al. (1996) study may have been compromised by the fact that patients were already receiving clozapine when they were randomized to risperidone or to continue on clozapine. Thus, no baseline on typical neuroleptic drugs or neuroleptic withdrawal was ever obtained, and the baseline for 10 of the 20 subjects evaluated was obtained when these patients had already received clozapine for an unknown period of time. Thus, they may have achieved maximum improvement from clozapine treatment at the time the ratings were initiated. Lack of cognitive response to clozapine was unrelated to good symptom response. However, a previous history of good response to typical neuroleptic drugs appears to be a good predictor of improvement in cognition with clozapine: The three studies that found the most robust improvement in cognition in association with clozapine (Lee et al. 1994; Fujii et al. 1997; Galletly et al. 1997) included patients who responded best to typical neuroleptic drugs. In contrast, it appears that the most treatment-resistant patients (e.g., in Lindenmayer et al. 1998 ) had the least robust improvement in cognition. This suggests that the capacity to respond to typical neuroleptic drugs in terms of psychopathology may predict the capacity to demonstrate significant improvement in cognition when treated with clozapine. If this is confirmed in future studies, it would provide additional rationale for the use of clozapine in patients whose positive symptoms had responded to typical neuroleptic drugs.
Clozapine's ability to improve attention and verbal fluency, which appears to be quite robust, has been found in the majority of studies to date. There is no evidence that practice effects account for the beneficial effects of clozapine on cognition. Even in the case of verbal fluency, where clozapine has been found to produce improvement in six of seven studies, no improvement has been found with risperidone (Meltzer, unpublished data) . Moreover, Kenny and Meltzer (1992) found no evidence of a practice effect on any of the cognitive measures in the studies of Hagger et al. (1993) or Lee et al. (1994) . The apparent improvement of verbal learning and memory may affect three areas of outcome identified by Green (1996) : community outcome, social problem solving, and skill acquisition. As previously mentioned, these outcome measures are related to performance on measures of verbal learning and memory. We found significant relationships between improvement in cognitive measures with clozapine and quality of life (Meltzer et al., unpublished data) .
The effects of baseline performance, gender, duration of illness, duration of treatment, dosage, and adjunctive therapies on the effect of clozapine on cognition require further study. It is also unclear which cognitive changes occurring from clozapine treatment are associated with changes in psychopathology. Hagger et al. (1993) did find that improvement in negative symptoms was associated with improvement in attention, executive function, verbal learning and memory, and verbal fluency. It is interesting that improvement in positive symptoms did not predict improvement in cognitive function. However, Galletly et al. (1997) also found that improvement in psychopathology, including positive symptoms, correlated with improvement in various cognitive measures. Clearly, some changes in cognitive performance are associated with changes in psychopathology.
Risperidone. Risperidone is the second atypical antipsychotic drug introduced into clinical practice. Its effects on EPS and psychopathology are much more dosedependent than clozapine and possibly olanzapine as well (Marder and Meibach 1994; Peuskens 1995) . At doses £ 6 to 8 mg/day, it usually produces few EPS. At higher doses, the frequency of EPS increases and there is some evidence for lesser efficacy as well (Lindstrom and von Knorring 1994; Marder and Meibach 1994; Simpson and Lindenmayer 1997 ). Whether cognitive effects of risperidone are also dose-related has not yet been determined.
Baseline cognitive data are available in three published studies of the effect of risperidone on cognition McGurk et al. 1997; Rossi et al. 1997 ) (table 4). Data from the same study of risperidone vs. haloperidol in treatment-resistant schizophrenia have been published by the UCLA group in several publications Kern et al. 1998 Kern et al. , 1999 ). In addition, we will provide a preliminary report on an open study of the effect of risperidone in schizophrenia. The UCLA study ) was the only doubleblind study and included haloperidol as a comparator. The total number of subjects treated with risperidone in these studies was 123, with individual sample sizes ranging from 13 to 29. The studies of Green et al. (1997) and Rossi et al. (1997) included neuroleptic-resistant patients with schizophrenia. The other two studies included both neuroleptic-resistant and neuroleptic-responsive patients (Stipp and Lussier 1996; Meltzer et al., in preparation) . The duration of treatment ranged from 4 weeks to 6 months. A small proportion of subjects treated with risperidone received anticholinergic medications for EPS in all the studies.
The preliminary results of our open study of risperidone on cognition in 29 patients with schizophrenia will be reported here. The methods of diagnosis and assessment were identical to those of Hagger et al. (1993) and Lee et al. (1994) . There were 22 males and 7 females (mean age 29.3 ± 7.5 years; duration of illness, 9 ± 3.4 years). Of these, 6 patients were hospitalized during an acute exacerbation at the time of study entry and 23 were outpatients. Eleven of the patients met the criteria of Kane et al. (1988) for neuroleptic resistance. Cognition was assessed at baseline and repeated after 6 weeks of risperidone treatment. At that time, three patients were receiving benztropine for EPS. Other psychotropic medications at 6 weeks included phenergan (3 patients) and lorazepam (2 patients). There was no significant change in BPRS total, positive, or withdrawal/retardation scores at 6 weeks, reflecting in part the neuroleptic-resistant nature of this group. Improvement in the ACTT, a measure of verbal working memory, at 6 weeks (29.3 ± 8.0 to 32.3 ± 11.6; p < 0.05) was the only significant change. There was a trend for an improvement in the WCST-Categories (p < 0.09).
Before we review all the studies that have evaluated the effects of risperidone on cognitive functioning in schizophrenia, we will comment on two studies not included in this review. Gallhofer et al. (1996) evaluated the comparative effects of risperidone, clozapine, and typical antipsychotics on maze performance. The evaluation was done after treatment with these medications for an unspecified amount of time. No baseline assessments on other medications were obtained prior to study entry; therefore, change from baseline on cognitive measures was not known, and any time-dependent effects of these medications were not evaluated. Daniel et al. (1996) randomized treatment-resistant schizophrenia patients who had been stable on clozapine to receive either clozapine or risperidone. Again, no baseline assessments prior to clozapine or risperidone treatment were obtained. Subjects who were randomized to receive clozapine had (Stipp and Lussier 1996) , but two other measures of attention, Divided Attention and Digit Span Forward, did not improve (Rossi et al. 1997; Stipp and Lussier 1996) . Reaction time was reported to be improved by risperidone (Stipp and Lussier 1996; Kern et al. 1998) . Improvements compared to baseline levels ranged from approximately 10 percent on the DSST to approximately 20 percent on the serial reaction time test. However, despite significant improvements, performance remained impaired compared to normal control subjects.
Executive function. Two of three studies (table 5) found improvement in measures of executive function, which included the WCST-Categories and Total Errors and Trail Making B Rossi et al. 1997) . The improvement in the WCST-Categories reported by Rossi et al. (1997) was 0.5 categories; how- ever, performance remained in the impaired range. A trend for improvement in the WCST was found in the study of Meltzer et al. (in preparation) . Similarly, performance on Trail Making B improved approximately 15 percent from baseline in the study of McGurk et al. (1997) but remained in the clinically impaired range. Working memory. All three studies that evaluated the effect of risperidone in verbal working memory (Rossi et al. 1997; Green et al. 1997; Meltzer et al., in preparation) (table 5 ) demonstrated improvement following risperidone treatment. It is interesting that each of these studies used a different measure of this construct. The degree of improvement in each study was about 10 to 15 percent above baseline levels. Despite improvement, performance in all cases remained impaired compared to normal scores.
Only one study evaluated the effects of risperidone on spatial working memory, which was also improved by risperidone treatment . The number of correctly identified target locations improved approximately 10 percent from baseline levels but remained significantly impaired compared to a control group matched for education.
Verbal learning and memory. Two of three studies (table 5) found improvement in verbal learning and memory (Stipp and Lussier 1996; Kern et al. 1999, this issue) . The improvement in total words acquired in the Kem et al. study was a full SD above baseline levels. For the haloperidol group, an increase of 0.25 SD from baseline was found. There were no measures of visual learning and memory included in any study.
Verbal fluency. Verbal fluency (table 5) as measured by the CWAT and CIGT was not improved in the study by Meltzer et al. (in preparation) . No other study included measures of verbal fluency.
Motor functioning. One study evaluated the effects of risperidone on a test of fine motor control, the Pin Test (table 5) . Fine motor control improved following risperidone treatment (Kern et al. 1998) . Risperidonetreated patients improved 15 percent from baseline; those treated with haloperidol improved only 6 percent.
Motor learning. Kern et al. (1998) evaluated the effects of risperidone on motor learning using the pursuit rotor and the serial reaction time test (table 5) . No improvement was found on either test.
Summary. Risperidone was found to have statistically significant effects on some measures of perceptual/motor processing, reaction time, executive function, working memory, verbal learning and memory, and motor function, but not verbal fluency or motor learning. In the UCLA study Green et al. 1997; Kern et al. 1999 , this issue), which was a randomized comparison of risperidone and haloperidol in treatmentresistant patients, changes in psychopathology did not account for the observed improvements in neurocognitive performance. Similarly, risperidone-induced improvement in working memory in the Meltzer et al. (in preparation) study was unrelated to improvement in BPRS total scores.
Olanzapine. Olanzapine is an atypical antipsychotic drug that has been found to be equal or superior to haloperidol in efficacy and to produce significantly fewer EPS than haloperidol (Beasley et al. 1996; Tollefson et al. 1997b; Tran et al. 1997 ). There are, to our knowledge, no published studies of the efficacy of olanzapine on cognition in schizophrenia. We report here data from 20 schizophrenia patients, 5 of whom were hospitalized on a research unit and 15 outpatients at baseline. Of the 20 patients, 10 (6 females, 14 males) met Kane et al. (1988) criteria for neuroleptic-resistant schizophrenia. The other 10 were at least partial responders to neuroleptic drugs. Mean age of the subjects was 41 ±9.0 years. Age at onset was 25 ± 6.0 years, and the mean duration of illness was 16.0 ± 7.3 years. The average education of the subjects was 13.3 ±2.5 years.
The initial evaluation of cognitive function was conducted while patients were receiving typical neuroleptic drugs and included two patients who received thioridazine. Ancillary medication at baseline included lorazepam and benztropine. The cognitive domains assessed included executive functioning, working memory, verbal and visual learning and memory, motor functioning, and perceptual/motor processing. Cognitive testing was repeated after 6 weeks of treatment. The mean dose of olanzapine was 12.5 ± 5.2 (range 5-20) mg/day. No other antipsychotic drug was given. Three subjects received lorazepam; two, sertraline; one, benztropine; and one, valproate at the 6-week assessment.
There was a trend for improvement in BPRS total score (p < 0.06) but no significant effect on BPRS positive or negative symptoms, perhaps reflecting the facts that half the patients in the study were neuroleptic resistant and the dose in this study was relatively low. The positive results are listed in table 6. A full published report is forthcoming. Olanzapine produced significant improvement on one measure of executive function, verbal learning and memory, verbal fluency, and reaction time. There was a 30 percent decrease in serial reaction time, which placed performance in the range of normal control subjects . The improvement in the Stroop Color-Word Interference Test was approximately 45 percent of baseline, which is one of the larger effects on cognition reported for any of the atypical antipsychotic drugs. The 6-week score on the Stroop test was within the range of normal controls (Hoff et al. 1992) . The improvement in the California Verbal Learning Test (Delis et al. 1983 ) List A trials 1 to 5 was 21 percent above baseline, whereas that in the Long Delay Free Recall was 17 percent. The improvement in verbal fluency as measured by the CWAT and the CIGT was 23 percent and 21 percent, respectively. This compares favorably with that seen with clozapine in neurolepticresistant patients: 15.1 percent and 5.5 percent, respectively (Hagger et al. 1993) . Olanzapine had no effect on the WCST-Categories or Percent Perseveration, the WISC-R Mazes, or Trail Making A and B, all of which are measures of executive functioning. It also had no effect on verbal and spatial working memory or the DSST and Digit Span tests, which are measures of perceptual/ motor processing and attention. It is unlikely that the positive effects on cognition reflect practice effects because typical neuroleptic drugs at 6 weeks did not produce improvement in these same tests of executive function, verbal learning and memory, or verbal fluency. These findings, of course, need to be verified in an independent sample. In summary, olanzapine was found to have a significant effect on some measures of reaction time, executive function, verbal learning and memory, and verbal fluency. The magnitude of these effects was generally greater than that previously reported for clozapine and risperidone. However, these are the results of only one study and must be confirmed by other laboratories, in comparison with other atypical agents, using a double-blind, randomized experimental design.
Quetiapine. There are no published data on the effect of quetiapine on cognition except for a single case study, which reported significant improvement in attention and verbal memory and learning (Stipp and Lussier 1996) .
Comparison of Clozapine, Risperidone, and
Olanzapine. Even at this early stage of research, there are similarities as well as differences among these three atypical antipsychotic drugs with regard to which domains of cognition are improved after short-term treatment. It is important to point out that each of the drugs produced some improvement in cognition, whereas the data for typical neuroleptic drugs suggest no consistent improvement in any cognitive measure across many studies.
Clozapine appears to favorably affect most cognitive domains, albeit to varying extents. Olanzapine did not improve visual learning and memory, although it did improve verbal learning and memory. There are no data with regard to risperidone and visual learning and memory. Risperidone improved all cognitive domains except verbal fluency. Clozapine, olanzapine, and risperidone all appear to improve some, but not all, tests of perceptual/ motor processing, attention/reaction time, executive function, and verbal learning and memory. Clozapine and olanzapine, but not risperidone, were found to improve verbal fluency. The major beneficial effects of both clozapine and olanzapine were on verbal fluency, followed by verbal learning and memory. Overall the effects of the two drugs on cognition were similar. The lack of effect of risperidone on verbal fluency has been reported by only one laboratory so far. It will be necessary to replicate this study in other laboratories before this difference wiih clozapine and olanzapine can be accepted.
Our laboratory (Hagger et al. 1993; Lee et al. 1994) failed to observe improvement with either clozapine or olanzapine on verbal working memory, but Galletly et al. (1997) did report improvement with clozapine. Risperidone differed from both other drugs in having its most robust effect on working memory, but it also improved attention and verbal learning and memory. There was stronger evidence for risperidone to improve executive function, including the WCST, than for either of the other two drugs.
The fact that clozapine and olanzapine have anticholinergic properties, while risperidone does not, is a possible basis for their differential impact on working memory. Clozapine and olanzapine have a greater ability to increase the concentration of extracellular DA in awake, freely moving rats than does risperidone (Kuroki et al. 1998 ). However, all three drugs produce high occupancy of cortical 5-HT 2a receptors in the human cortex (Farde et al. 1992; Nyberg et al. 1993 Nyberg et al. , 1997 . These results suggest that ACh may be more important than DA or 5-HT for working memory function. This is in accord with previous data from rodents, which indicates that ACh is more important than DA for short-term memory (McGurk et al. 1992; Broersen et al. 1994 Broersen et al. , 1995 .
The differences among drugs noted here did not arise from direct comparisons in randomized, double-blind trials. Thus, it is possible that reported differences reflect differences in patient populations, medication status at baseline, drug dosage, duration of trials, choice of specific cognitive tests, and concomitant medication. However, the fact that key differences on working memory and verbal fluency reflect studies from multiple laboratories, at least for some of the drugs, suggests these differences may be real.
Clinical Significance. The studies reviewed here could have rich significance for clinical practice if the results are confirmed and extended by further research. It is not yet clear if the magnitude of the improvement in cognition reported here for any of these drugs is clinically significant. There is evidence that verbal learning and memory, in particular, is important for occupational and community functioning, as summarized by Green (1996) . Ail three atypical antipsychotic drugs have a comparable beneficial effect on this cognitive domain. Risperidone appears to have a robust effect on working memory, a cognitive dimension thought to be of great importance to the entire schizophrenia syndrome (Goldman-Rakic 1991) . Although the average improvement in cognitive measures appears to be about 0.5 SD, this may be sufficient to improve cognition in many patients to the point where they could function in many situations at an accept-able level. Data from Lindstrom (1988) and Meltzer (1992) indicated that a significant proportion of patients on clozapine are able to work part-or full-time after 1 or more years of treatment The differential contributions to improved outcome of the enhanced cognitive functioning, decreased psychopathology, and lower EPS produced by the atypical antipsychotic drugs are not known.
The available data suggest that the improvement in cognitive function produced by the atypical antipsychotic drugs is, in general, independent of the improvement in psychopathology. This is consistent with the evidence that cognitive measures generally correlate poorly with psychopathology, especially positive symptoms (Hagger et al. 1993) . It also suggests that the cognitive impairment in schizophrenia is to some extent the result of brain abnormalities independent of those that produce major psychopathology.
If it is confirmed that specific atypical antipsychotic drugs have unique profiles of action on various domains of cognition, several interesting conclusions emerge. First, it may be desirable to characterize patients with schizophrenia on the basis of their deficits in specific domains of cognition and choose the antipsychotic drug most likely to correct that deficit, providing it is in the range where the drug is effective. For example, risperidone may be prescribed for patients with particular deficits in working memory and executive function, and clozapine or olanzapine for patients with deficits in verbal fluency. Of course, the patterns of cognitive deficits that patients exhibit may differ from the pattern the drugs affect. This raises the second issue: Would it be useful to combine atypical antipsychotic drugs for such patients to attempt to obtain the advantages of both? Such a strategy would have to consider the combined side-effect burden and the cost. Anecdotal reports of advantages of clozapine plus risperidone or olanzapine have been difficult to explain pharmacologically. Additive effects on cognition could be the basis for the beneficial effects of such combinations. However, expense and side-effect profiles make this strategy one to pursue with caution. It is also possibile that in combination, the drugs' effects will negate each other. Third, there is a strong need to determine which factors affect the ability of the atypical antipsychotic drugs to improve cognition-for example, gender, duration of illness, age, concomitant medications, and neuroleptic-resistant status. These and other such issues will require extensive clinical study.
Cholinergic and Serotonergic Basis for Effects of
Atypical Antipsychotic Drugs on Cognition. Keefe et al. (1999, this issue) reviewed some of the literature concerning the importance of ACh, DA, 5-HT, NE, and glutamate to the cognitive effects of antipsychotic drugs.
Several issues concerning ACh and 5-HT not addressed there will be highlighted here. The first is the common belief that the sole effect of clozapine on cholinergic transmission is as a potent muscarinic antagonist. On this basis, clozapine has been predicted to interfere with various cognitive functions, especially the encoding of new information as required in tests of verbal memory (Harvey and Keefe 1997) . However, clozapine was reported to be a full agonist at the M 4 receptor in Chinese hamster ovary cells transfected with the human cloned MJ-MJ receptor genes (Zom et al. 1994) . It was subsequently shown to be a partial agonist at cloned M 4 receptors and a full antagonist at striatal M 4 receptors (Olianas et al. 1997) . Perhaps more important, clozapine has recently been reported to increase extracellular concentrations of ACh in rat prefrontal cortex, nucleus accumbens, and striatum using in vivo microdialysis (Parada et al. 1997) . We have confirmed these results for the prefrontal cortex (Ichikawa and Meltzer, unpublished data). The increase is sufficiently large that it might be able to overcome the muscarinic receptor blockade induced by clozapine. Thus, clozapine may be an indirect cholinergic agonist as well as a direct-acting muscarinic agonist or antagonist (Zorn et al. 1994) . If so, it might be expected to enhance encoding of memories, but should not affect verbal fluency (Broks et al. 1988 ).
Second, the hypothesis of Goldman-Rakic and colleagues about the central importance of working memory to the etiology of schizophrenia (Goldman-Rakic 1991; Goldman-Rakic and Selemon 1997) and of a modulatory role of dopaminergic activity (Sawaguchi and GoldmanRakic 1991) and appropriate levels of D, receptor stimulation (Zahn et al. 1994; Williams and Goldman-Rakic 1995) on working memory, in particular, has been very influential in guiding research in this area. It is consistent with the view that working memory depends on the activity of the prefrontal cortex and that increased dopaminergic activity, especially in the prefrontal cortex, is required during working memory (Sawaguchi and Goldman-Rakic 1991; Watanabe et al. 1997) . There is evidence for decreased blood flow in the dorsolateral prefrontal cortex in schizophrenia during the Wisconsin Card Sorting task, which requires both executive function and working memory Weinberger et al. 1986 ). However, recent discoveries of the localization of S-HTr eceptors on the apical dendrites of pyramidal neurons in the rat prefrontal cortex (Willins et al. 1997; Jakab and Goldman-Rakic 1998) have resulted in the hypothesis that S-HT^ receptors may be just as or more important for working memory as are Dj receptors. It has been postulated that clozapine exerts its beneficial effects on cognition and psychopathology by virtue of its ability to antagonize and downregulate 5-HT 2a receptors (Jakab and Goldman-Rakic 1998) . This is an attractive hypothesis, but it fails to explain why clozapine has so little effect on verbal working memory. There are as yet no data on its effects on spatial working memory. Furthermore, downregulation of S-HT^ receptors is also produced by antidepressants and typical neuroleptics, such as haloperidol and chlorpromazine (Peroutka and Snyder 1980; Andree et al. 1986) . We found that a single dose of clozapine will downregulate S-HT^ receptors and that this effect lasted for more than 5 days (Matsubara and Meltzer 1989) . No relationship between affinity for the 5-HT^ receptor of a group of antipsychotic drugs and downregulation of 5-HT 2a receptors was found (Matsubara and Meltzer 1989) . Further study is needed to determine the integrated effect of 5-HT, DA, and ACh on working memory and other cognitive measures.
In order to further study the pharmacological basis of the cognitive effects of the atypical antipsychotic drugs, valid data on which of the cognitive measures each drug affects in specific types of schizophrenia patients, and the time course of that effect, are essential. These findings must then be related to a comprehensive understanding of the in vivo effects of these drugs.
Conclusions
The studies of the effects of atypical antipsychotic drugs on cognitive function in schizophrenia reviewed here are the first efforts in this regard. There are clear limitations in the design of these studies, including patient selection, sample size, choice of cognitive tests, absence of comparators, lack of double-blind evaluations, duration of treatment, and concomitant medications. Nevertheless, the frequency with which positive effects have been reported contrasts strikingly with the results from studies of typical neuroleptics, where there have been few positive effects. Buchanan et al. (1994) , Lee et al. (1994) , Green et al. (1997), and McGurk et al. (1997) compared clozapine or risperidone with typical neuroleptic drugs and found advantages for the atypical agents over the typicals in a number of the cognitive measures. Together with data indicating that cognitive function is highly important to schizophrenia outcome, it is possible to conclude that the cognitive enhancing effects of atypical antipsychotic drugs represent a clinically important advantage over typical antipsychotic drugs. It is interesting to note that the atypical antipsychotic drugs were originally developed to enhance tolerability through diminished EPS, rather than to target cognitive functions.
The possibility that atypical antipsychotic drugs have differing patterns of effects on cognition while sharing some overall benefit implies differences in mechanism of action, which can be exploited to understand the pathophysiology of cognitive impairment in schizophrenia and its remediation. We suggest that cognitive improvement be made an explicit target of drug development for schizophrenia. Agents that improve working memory, executive function, attention, and verbal learning and memory should be possible with the aid of appropriate animal models, using a wide range of species. Whether such agents will prove to be antipsychotic in the traditional sense, that is, whether they decrease delusions and hallucinations as well, will be of great interest. Still, this would be of secondary importance because it might be possible to combine antipsychotic agents and cognitive enhancers to treat these two aspects of the syndrome. It is also intriguing to speculate that efforts to develop cognitive enhancing agents for senile dementia and age-associated cognitive decline may provide treatments valuable in schizophrenia and vice versa.
